Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial

C Loguercio, P Andreone, C Brisc, Mc Brisc, E Bugianesi, M Chiaramonte, C Cursaro, M Danila, I De Sio, A Floreani, Ma Freni, Antonio Grieco, Mario Groppo, R Lazzari, S Lobello, E Lorefice, M Margotti, Luca Miele, Silvia Milani, L OkolicsanyiG Palasciano, P Portincasa, P Saltarelli, A Smedile, F Somalvico, A Spadaro, I Sporea, P Sorrentino, R Vecchione, C Tuccillo, C Del Vecchio Blanco, A. Federico

Risultato della ricerca: Contributo in rivistaArticolo in rivista

159 Citazioni (Scopus)


The only currently recommended treatment for nonalcoholic fatty liver disease (NAFLD) is lifestyle modification. Preliminary studies of silybin showed beneficial effects on liver function. Realsil (RA) comprises the silybin phytosome complex (silybin plus phosphatidylcholine) coformulated with vitamin E. We report on a multicenter, phase III, double-blind clinical trial to assess RA in patients with histologically documented NAFLD. Patients were randomized 1:1 to RA or placebo (P) orally twice daily for 12 months. Prespecified primary outcomes were improvement over time in clinical condition, normalization of liver enzyme plasma levels, and improvement of ultrasonographic liver steatosis, homeostatic model assessment (HOMA), and quality of life. Secondary outcomes were improvement in liver histologic score and/or decrease in NAFLD score without worsening of fibrosis and plasma changes in cytokines, ferritin, and liver fibrosis markers. We treated 179 patients with NAFLD; 36 were also HCV positive. Forty-one patients were prematurely withdrawn and 138 patients analyzed per protocol (69 per group). Baseline patient characteristics were generally well balanced between groups, except for steatosis, portal infiltration, and fibrosis. Adverse events (AEs) were generally transient and included diarrhea, dysgeusia, and pruritus; no serious AEs were recorded. Patients receiving RA but not P showed significant improvements in liver enzyme plasma levels, HOMA, and liver histology. Body mass index normalized in 15% of RA patients (2.1% with P). HCV-positive patients in the RA but not the P group showed improvements in fibrogenesis markers. This is the first study to systematically assess silybin in NAFLD patients. Treatment with RA but not P for 12 months was associated with improvement in liver enzymes, insulin resistance, and liver histology, without increases in body weight. These findings warrant further investigation.
Lingua originaleEnglish
pagine (da-a)1658-1665
Numero di pagine8
Stato di pubblicazionePubblicato - 2012


  • non alcoholic fatty liver disease
  • silybin
  • trial


Entra nei temi di ricerca di 'Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial'. Insieme formano una fingerprint unica.

Cita questo